[C:1]([Cl:4])(=O)C.C(O[C:10]([N:12]1[CH2:17][CH2:16][C:15]([O:21][CH3:22])([C:18]([OH:20])=[O:19])[CH2:14][CH2:13]1)=O)(C)(C)C.C(=O)([O-])[O-].[Na+].[Na+].ClC1[N:35]=[CH:34][C:33]([B:36]([OH:38])[OH:37])=[CH:32][N:31]=1>CO.C(O)C>[ClH:4].[CH3:22][O:21][C:15]1([C:18]([O:20][CH3:1])=[O:19])[CH2:14][CH2:13][N:12]([C:10]2[N:35]=[CH:34][C:33]([B:36]([OH:38])[OH:37])=[CH:32][N:31]=2)[CH2:17][CH2:16]1A 2% solution of HCl in MeOH was prepared by adding acetyl chloride (1.1 mL) to MeOH (25 mL). To this solution was added 1-[(tert-butoxy)carbonyl]-4-methoxypiperidine-4-carboxylic acid (1 g, 3.6637 mmol) and the solution was heated under reflux for 6 h. The reaction mixture was evaporated to dryness and left on a vacuum line for 30 minutes. The material thus obtained was dissolved in ethanol (8 mL) and stirred with sodium carbonate (0.96 g, 9.1 mmol) for 10 minutes, then (2-chloropyrimidin-5-yl)-boronic acid (0.57 g, 3.61 mmol) was added and the mixture was stirred at 60° C. for 6 h. The reaction mixture was filtered through celite and the solvents removed in vacuo to give the title compound (0.8 g, 71%) as a white foam, which was used without further purification. LCMS (pH 10) MH+ 296, RT 0.86 minutes.
Loading…